Component information
No US or EU label exists for this exact combination, so information is shown for each component.
Use: Uses For the temporary relief of pain and itching associated with: insect bites minor cuts minor burns sunburn scrapes minor skin irritations rashes due to poison ivy, poison oak, or poison sumac US FDA label
- caraway no separate page
- cochineal no separate page
- glycyrrhiza no separate page
- rhubarb no separate page
- senna no separate page
Use: to raise plasma pH in adult and pediatric patients with clinically significant metabolic acidosis. US FDA label
Kidney dosing: Sodium bicarbonate (single-agent)Show full dosing details
- CrCl ≥60 mL/min
- IV for metabolic acidosis (adults and children 2 years and older): 2 to 5 mEq/kg over 4 to 8 hours, by bicarbonate, total CO2, pH and clinical state (label). Treat the cause.
- CrCl 30–59 mL/min
- No kidney dose change in the label. Kidney disease and anuria increase sensitivity to the sodium load: watch for fluid overload, edema and blood pressure, and adjust other sodium sources (label 5.1). Monitor bicarbonate, sodium and potassium; avoid overshoot alkalosis. Oral tablets for CKD metabolic acidosis: consider treatment to keep serum bicarbonate from falling below 18 mmol/L, and do not overshoot the upper limit of normal; watch blood pressure, potassium and fluid status (KDIGO 2024 PP 3.10.1, 3.10.2). Each 650 mg tablet supplies about 7.7 mEq of sodium and bicarbonate (325 mg about 3.9 mEq); 8.4% solution is 1 mEq/mL (84 mg per mEq; label 3: 12.6 mg/mL = 0.150 mEq/mL). Oral doses are not in the label.
- CrCl 15–29 mL/min
- No kidney dose change in the label. Kidney disease and anuria increase sensitivity to the sodium load: watch for fluid overload, edema and blood pressure, and adjust other sodium sources (label 5.1). Monitor bicarbonate, sodium and potassium; avoid overshoot alkalosis. Oral tablets for CKD metabolic acidosis: consider treatment to keep serum bicarbonate from falling below 18 mmol/L, and do not overshoot the upper limit of normal; watch blood pressure, potassium and fluid status (KDIGO 2024 PP 3.10.1, 3.10.2). Each 650 mg tablet supplies about 7.7 mEq of sodium and bicarbonate (325 mg about 3.9 mEq); 8.4% solution is 1 mEq/mL (84 mg per mEq; label 3: 12.6 mg/mL = 0.150 mEq/mL). Oral doses are not in the label.
- CrCl <15 mL/min (not on dialysis)
- No kidney dose change in the label. Kidney disease and anuria increase sensitivity to the sodium load: watch for fluid overload, edema and blood pressure, and adjust other sodium sources (label 5.1). Monitor bicarbonate, sodium and potassium; avoid overshoot alkalosis. Oral tablets for CKD metabolic acidosis: consider treatment to keep serum bicarbonate from falling below 18 mmol/L, and do not overshoot the upper limit of normal; watch blood pressure, potassium and fluid status (KDIGO 2024 PP 3.10.1, 3.10.2). Each 650 mg tablet supplies about 7.7 mEq of sodium and bicarbonate (325 mg about 3.9 mEq); 8.4% solution is 1 mEq/mL (84 mg per mEq; label 3: 12.6 mg/mL = 0.150 mEq/mL). Oral doses are not in the label.
- Hemodialysis (intermittent)
- No dose change; anuria raises the risk of fluid overload from the sodium load (label 5.1). Dialysate bicarbonate also corrects acidosis; coordinate with the dialysis prescription (clinical judgment).
- Peritoneal dialysis
- No dose change; watch sodium load and fluid status (label 5.1).
- CRRT
- No data in label. CRRT fluids are usually bicarbonate-buffered; added IV bicarbonate is a specialist decision guided by blood gases.
- Dialyzable? Bicarbonate crosses dialysis membranes in both directions according to the dialysate bicarbonate concentration (physiology; not stated in label).
- Monitoring Blood gases or serum bicarbonate, sodium, potassium (hypokalemia as acidosis corrects), fluid status, blood pressure, edema. Extravasation site (hypertonic solutions).
From the Sodium bicarbonate monograph (renalcarematters.com, reviewed).
Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney dosing for each component (single-agent) is shown under Component information.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- Syrup: 260 mg/260 mg/130 mg/25 mg/25 mg/10 mg/5 mg/5 mg
Registered products in the Philippines
1 product registered with the Food and Drug Administration (FDA) Philippines list Camphor + Caraway + Cochineal + Glycyrrhiza + Rhubarb + Senna + Sodium bicarbonate as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
CarminasenSenna (Cassia acutifolia) + Glycyrrhiza (Glycyrrhiza glabra) + Rhubarb (Rheum rhabarbarum) + Caraway (Carum carvi) + Sodium Bicarbonate + Cochineal (Dactylopius coccus) + Camphor | 260 mg/ 260 mg/ 130 mg/ 25 mg/25 mg/10 mg/5 mg/ 5 mg SyrupAmber glass bottle x 30 mL (Box of 1's) | OTC | Hizon Laboratories, Inc.Philippines | Boie Incorporated | DR-XY24594 | Jan 26, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .